NVO
Novo Nordisk
DRUG MANUFACTURERS - GENERAL · HEALTHCARE
Novo Nordisk A/S (NVO) is a leading global healthcare company based in Bagsvaerd, Denmark, with a primary focus on diabetes care, obesity management, and hormone replacement therapies. Renowned for its commitment to innovation and research, Novo Nordisk utilizes advanced biotechnology to develop hig...
$45.07
+1.78% (+$0.79)
Volume
10.67M
52W High
$80.56
52W Low
$35.12
Market Cap
$198.96B
What to Watch This Quarter
Based on historical dataConsensus EPS
$5.19
Whisper EPS
$5.21
0.3% above consensus
Last Quarter
$6.63
Current Streak
2 Misss
Avg Surprise (4Q)
-2.37%
Next Earnings Report
Reports in 75 days
Price Chart
EPS History: Consensus vs Actual
Last 12 quartersPrice Movement Around Earnings
Q1 2026
May 6, 2026
1-Day:
+0.09%
5-Day:
+1.40%
Q1 2026
May 5, 2026
1-Day:
+1.98%
Q4 2025
Feb 3, 2026
1-Day:
-6.18%
Q3 2025
Nov 5, 2025
1-Day:
-4.02%
5-Day:
-5.05%
Revenue & Financial Performance
Revenue Whisper
$89.77B
TWN Proprietary Estimate
Last Quarter Revenue
$96.82B
+24.0% YoY
Gross Margin
86.0%
Net Margin: 50.2%
| Quarter | Revenue | YoY Growth | Gross Margin | Op Margin | Net Income |
|---|---|---|---|---|---|
| Q1'26 | $96.82B | +24.0% | 86.0% | 61.6% | $48.56B |
| Q4'25 | $79.14B | -7.6% | 80.9% | 40.1% | $26.89B |
| Q3'25 | $74.98B | +5.1% | 76.1% | 31.6% | $20.01B |
| Q2'25 | $76.86B | +12.9% | 83.3% | 43.5% | $26.50B |
| Q1'25 | $78.09B | +19.5% | 83.5% | 49.7% | $29.03B |
| Q4'24 | $85.68B | +30.1% | 84.8% | 42.9% | $28.23B |
| Q3'24 | $71.31B | +21.4% | 84.1% | 47.4% | $27.30B |
| Q2'24 | $68.06B | +25.3% | 84.9% | 38.1% | $20.05B |
Company Information
Symbol
NVO
Company
Novo Nordisk
Market Cap
$198.96B
Sector
HEALTHCARE
Next Earnings
Aug 5, 2026
Also Reporting Soon
Companies reporting earnings around the same time as NVO
HEALTHCARE Stocks
Other healthcare companies with earnings data
More in DRUG MANUFACTURERS - GENERAL
Compare NVO with competitors
Side-by-side earnings comparison